A Phase II Study of XELOX in Locally Advanced or Metastatic Gastric Cancer
- Determine the response proportion in patients with locally advanced, unresectable, or
metastatic gastric cancer treated with capecitabine and oxaliplatin.
- Determine the tolerability and toxicity of this regimen in these patients.
- Determine the median and progression-free survival of patients treated with this
OUTLINE: This is an open-label study.
Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on
days 1-7. Treatment repeats every 14 days in the absence of unacceptable toxicity or disease
After completion of study treatment, patients are followed every 3 months for 1 year, every
6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Uzair B. Chaudhary, MD
Medical University of South Carolina
United States: Federal Government
|Hollings Cancer Center at Medical University of South Carolina||Charleston, South Carolina 29425|